Clinical significance of microRNA-24 expression in esophageal squamous cell carcinoma

Neoplasma

Volumn 62, Issue 2, 2015, Pages 250-258

  Dong, W ^a,b   Li, B ^b   Wang, Z ^a,b   Zhang, Z ^b   Wang, J ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Chemo radiation therapy; Esophageal squamous cell carcinoma; MiR 24 expression; Radiosensitivity

Indexed keywords

FLUOROURACIL; MICRORNA 24;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; RADIATION DOSE; RADIOSENSITIVITY; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; TUMOR DIFFERENTIATION; UPREGULATION;

EID: 84943655900     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2015_030     Document Type: Article

References (46)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA: a cancer journal for clinicians 2011; 61: 69-90. http://dx.doi.org/10.3322/caac.20107
2. Schneider BJ, Urba SG. Preoperative chemoradiation for the treatment of locoregional esophageal cancer: The standard of care? Seminars in radiation oncology 2007; 17: 45-52. http://dx.doi.org/10.1016/j.semradonc.2006.09.002
3. Shibata T, Kokubu A, Saito S, Narisawa-Saito M, Sasaki H, et al. Nrf2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia 2011; 13: 864-873.
4. Luthra R, Wu TT, Luthra MG, Izzo J, Lopez-Alvarez E, et al. Gene expression profiling of localized esophageal carcinomas: Association with pathologic response to preoperative chemoradiation. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2006; 24: 259-267. http://dx.doi.org/10.1200/JCO.2005.03.3688
5. Wu X, Gu J, Wu TT, Swisher SG, Liao Z, et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2006; 24: 3789-3798. http://dx.doi.org/10.1200/ICQ.2005.03.6640
6. Edge SB, Compton CC. The american joint committee on cancer: The 7th edition of the ajcc cancer staging manual and the future of tnm. Annals of surgical oncology 2010; 17: 1471-1474. http://dx.doi.org/10.1245/s10434-010-0985-4
7. Liu N, Cui RX, Sun Y, Guo R, Mao YP, et al. A four-mirna signature identified from genome-wide serum mirna profiling predicts survival in patients with nasopharyngeal carcinoma. International journal of cancer. Journal international du cancer 2013.
8. Zhang JX, Tong ZT, Yang L, Wang F, Chai HP, et al. Pitx2: A promising predictive biomarker of patients‘ prognosis and chemoradioresistance in esophageal squamous cell carcinoma. International journal of cancer. Journal international du cancer 2013; 132: 2567-2577. http://dx.doi.org/10.1002/ijc.27930
9. Esquela-Kerscher A, Slack FJ. Oncomirs - micrornas with a role in cancer. Nature reviews. Cancer 2006; 6: 259-269. http://dx.doi.org/10.1038/nrc1840
10. Blandino G, Fazi F, Donzelli S, Kedmi M, Sas-Chen A, et al. Tumor suppressor micrornas: A novel non-coding alliance against cancer. FEBS letters 2014. http://dx.doi.org/10.1016/j.febslet.2014.03.033
11. Bouyssou JM, Manier S, Huynh D, Issa S, Roccaro AM, et al. Regulation of micrornas in cancer metastasis. Bio-chim Biophys Acta 2014; 1845: 255-265.
12. WESTERMANN AM, SCHMIDT D, HOLDENRIEDER S, MORITZ R, SEMJONOW A, et al. Serum micrornas as biomarkers in patients undergoing prostate biopsy: Results from a prospective multi-center study. Anticancer research 2014; 34: 665-669.
13. DIAO Y, GUO X, JIANG L, WANG G, ZHANG C, et al. Mir-203, a tumor suppressor frequently down-regulated by promoter hypermethylation in rhabdomyosarcoma. The Journal of biological chemistry 2014; 289: 529-539. http://dx.doi.org/10.1074/jbc.M113.494716
14. Menendez P, Padilla D, Villarejo P, Palomino T, Nieto P, et al. Prognostic implications of serum microrna-21 in colorectal cancer. Journal of surgical oncology 2013; 108: 369-373. http://dx.doi.org/10.1002/iso.23415
15. Zhao S, Yao D, Chen J, Ding N. Circulating mirna-20a and mirna-203 for screening lymph node metastasis in early stage cervical cancer. Genetic testing and molecular biomarkers 2013; 17: 631-636. http://dx.doi.org/10.1089/gtmb.2013.0085
16. Kobayashi E, Hornicek F, Duan Z. Microrna involvement in osteosarcoma. Sarcoma 2012; 2012: 359739.
17. Li ZH, ZHANG H, YANG ZG, WEN GQ, CUi YB, et al. Prognostic significance of serum microrna-210 levels in nonsmall-cell lung cancer. The Journal of international medical research 2013.
18. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. Circulating micrornas as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America 2008; 105: 10513-10518. http://dx.doi.org/10.1073/pnas.0804549105
19. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microrna biomarkers in plasma and serum using quantitative reverse transcription-pcr (qrt-pcr). Methods 2010; 50: 298-301. http://dx.doi.org/10.1016/i.ymeth.2010.01.032
20. Qian L, Van Laake LW, Huang Y, Liu S, Wend-Land MF, et al. Mir-24 inhibits apoptosis and represses bim in mouse cardiomyocytes. The Journal of experimental medicine 2011; 208: 549-560. http://dx.doi.org/10.1084/iem.20101547
21. Wang Q, Huang Z, Xue H, Jin C, Ju XL, et al. Microrna mir-24 inhibits erythropoiesis by targeting activin type i receptor alk4. Blood 2008; 111: 588-595. http://dx.doi.org/10.1182/blood-2007-05-092718
22. Lal A, Kim HH, Abdelmohsen K, Kuwano Y, Pull-Mann R, JR., et al. P16(ink4a) translation suppressed by mir-24. PloS one 2008; 3: e1864.
23. LAL A, PAN Y, NAVARRO F, DYKXHOORN DM, MOREAU L, et al. Mir-24-mediated downregulation of h2ax suppresses DNA repair in terminally differentiated blood cells. Nature structural & molecular biology 2009; 16: 492-498. http://dx.doi.org/10.1038/nsmb.1589
24. Lal A, Navarro F, Maher CA, Maliszewski LE, Yan N, et al. Mir-24 inhibits cell proliferation by targeting e2f2, myc, and other cell-cycle genes via binding to “seedless” 3‘utr microrna recognition elements. Molecular cell 2009; 35: 610-625. http://dx.doi.org/10.1016/!.molcel.2009.08.020
25. <152624dsz.Pdf>.
26. Lin SC, Liu CJ, Lin JA, Chiang WF, Hung PS, et al. Mir-24 up-regulation in oral carcinoma: Positive association from clinical and in vitro analysis. Oral oncology 2010; 46: 204-208. http://dx.doi.org/10.1016/i.oraloncology.2009.12.005
27. CAO M, Seike M, Soeno C, Mizutani H, Kitamura K, et al. Mir-23a regulates tgf-beta-induced epithelial-mesenchymal transition by targeting e-cadherin in lung cancer cells. international journal of oncology 2012; 41: 869-875.
28. To KH, Pajovic S, Gallie BL, Theriault BL. Regulation of p14arf expression by mir-24: A potential mechanism compromising the p53 response during retinoblastoma development. BMC cancer 2012; 12: 69. http://dx.doi.org/10.1186/1471-2407-12-69
29. Mishra PJ, Song B, Mishra PJ, Wang Y, Humeniuk R, et al. Mir-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. PloS one 2009; 4: e8445. http://dx.doi.org/10.1371/iournal.pone.0008445
30. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214. http://dx.doi.org/10.1002/1097-0142d981010D47: 1<207:: AiD-CNCR2820470134>3.0.C0; 2-6
31. Schmittgen TD, Lee EJ, Jiang J. High-throughput realtime pcr. Methods in molecular biology 2008; 429: 89-98. http://dx.doi.org/10.1007/978-1-60327-040-37
32. Fokas E, Weiss C, Rodel C. The role of radiotherapy in the multimodal management of esophageal cancer. Digestive diseases 2013; 31: 30-37. http://dx.doi.org/10.1159/000347170
33. Hu H, Gatti RA. Micrornas: New players in the DNA damage response. J Mol Cell Biol 2011; 3: 151-158. http://dx.doi.org/10.1093/imcb/miq042
34. Landau DA, Slack FJ. Micrornas in mutagenesis, genomic instability, and DNA repair. Seminars in oncology 2011; 38: 743-751. http://dx.doi.org/10.1053/i.seminoncol.2011.08.003
35. Yang X, Feng M, Jiang X, Wu Z, Li Z, et al. Mir-449a and mir-449b are direct transcriptional targets of e2f1 and negatively regulate prb-e2f1 activity through a feedback loop by targeting cdk6 and cdc25a. Genes & development 2009; 23: 2388-2393. http://dx.doi.org/10.1101/gad.1819009
36. Legesse-Miller A, Elemento O, Pfau SJ, Forman JJ, Tavazoie S, et al. Let-7 overexpression leads to an increased fraction of cells in g2/m, direct down-regulation of cdc34, and stabilization of wee1 kinase in primary fibroblasts. The Journal of biological chemistry 2009; 284: 6605-6609. http://dx.doi.org/10.1074/ibc.C900002200
37. Lim WK, Micklem G. Micrornas dysregulated in breast cancer preferentially target key oncogenic pathways. Molecular bioSystems 2011; 7: 2571-2576. http://dx.doi.org/10.1039/c1mb05181d
38. Yamakuchi M, Yagi S, Ito T Lowenstein CJ. Microrna-22 regulates hypoxia signaling in colon cancer cells. PloS one 2011; 6: e20291. http://dx.doi.org/10.1371/iournal.pone.0020291
39. ZHAO L, BODE AM, CAO Y DONG Z. Regulatory mechanisms and clinical perspectives of mirna in tumor radiosensitivity. Carcinogenesis 2012; 33: 2220-2227. http://dx.doi.org/10.1093/carcin/bgs235
40. Zaidi SK, Dowdy CR, Van Wijnen AJ, Lian JB, Raza A, et al. Altered runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a mir-24/mkp-7/mapk network. Cancer research 2009; 69: 8249-8255. http://dx.doi.org/10.1158/0008-5472.CAN-09-1567
41. QIN W, SHI Y, ZHAO B, YAO C, JIN L, et al. Mir-24 regulates apoptosis by targeting the open reading frame (orf) region of faf1 in cancer cells. PloS one 2010; 5: e9429. http://dx.doi.org/10.1371/journal.pone.0009429
42. XIE L, WANG T, YU S, CHEN X, WANG L, et al. Cell-free mir-24 and mir-30d, potential diagnostic biomarkers in malignant effusions. Clinical biochemistry 2011; 44: 216-220. http://dx.doi.org/10.1016/j.clinbiochem.2010.11.002
43. WANG X, TANG S, LE SY, LU R, RADER JS, et al. Aberrant expression of oncogenic and tumor-suppressive micrornas in cervical cancer is required for cancer cell growth. PloS one 2008; 3: e2557. http://dx.doi.org/10.1371/journal.pone.0002557
44. KUNISAKI C, IMADA T, YAMADA R, HATORI S, Kin-Bara K, et al. Prognostic factors after chemoradiotherapy for patients with inoperable esophageal squamous cell carcinoma. Hepato-gastroenterology 2006; 53: 366-371.
45. WAKATSUKI M, SUZUKI Y, NAKAMOTO S, OHNO T, ISHIKAWA H, et al. Clinical usefulness of cyfra 21-1 for esophageal squamous cell carcinoma in radiation therapy. Journal of gastroenterology and hepatology 2007; 22: 715-719.
46. YI Y, LI B, WANG Z, SUN H, GONG H, et al. Cyfra21-1 and cea are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma. Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals 2009; 14: 480-485. http://dx.doi.org/10.3109/13547500903180265